A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.

Summary: Multiple myeloma is a cancer that forms in a type of white blood cell, but one of its most painful effects is significant bone destruction. Scientists have discovered a specific culprit within the bone marrow immune system: "Th17" cells. In myeloma patients, these cells release a protein called IL-17 that acts like a fuel for bone-destroying cells (osteoclasts). Healthy people have immune cells that regulate this process, but myeloma patients lack these regulators. The study offers a promising solution: if doctors can use treatments to switch these immune cells from the destructive "Th17" type to a protective "Th1" type, they could stop the bone damage in its tracks.